C4 Therapeutics (CCCC) Research & Development (2019 - 2026)

C4 Therapeutics has reported Research & Development for 8 years, with the latest figure at $24.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 9.11% year-over-year to $24.6 million; the trailing twelve-month figure through Mar 2026 stood at $101.8 million (down 11.64% YoY), and the FY2025 full-year result was $104.2 million, down 5.78% from the prior year.
• Research & Development for Q1 2026 stood at $24.6 million, down from $25.0 million in the prior quarter.
• The five-year high for Research & Development was $32.5 million in Q4 2024, with the low at $22.5 million in Q1 2024.
• Average Research & Development over 5 years is $27.9 million, with a median of $28.3 million recorded in 2023.
• Year-over-year, Research & Development soared 34.51% in 2022 and slipped 23.16% in 2025.
• Tracing CCCC's Research & Development over 5 years: stood at $30.7 million in 2022, then retreated by 0.85% to $30.4 million in 2023, then rose by 6.98% to $32.5 million in 2024, then fell by 23.16% to $25.0 million in 2025, then dropped by 1.51% to $24.6 million in 2026.
• The last three Research & Development figures came in at $24.6 million (Q1 2026), $25.0 million (Q4 2025), and $26.0 million (Q3 2025), per Business Quant data.

Peer Comparison